Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno Sells 24,778 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 24,778 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the completion of the sale, the chief financial officer now directly owns 140,948 shares in the company, valued at $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Alexis Desieno also recently made the following trade(s):

• On Friday, January 3rd, Alexis Desieno sold 8,854 shares of Cardlytics stock. The shares were sold at an average price of $3.67, for a total value of $32,494.18.

Cardlytics Price Performance

CDLX stock opened at $3.37 on Wednesday. The firm has a 50 day moving average price of $3.47 and a 200-day moving average price of $3.73. Cardlytics, Inc. has a 52-week low of $2.76 and a 52-week high of $20.52. The firm has a market capitalization of $171.26 million, a price-to-earnings ratio of -0.55 and a beta of 1.54. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.

Hedge Funds Weigh In On Cardlytics

Several large investors have recently made changes to their positions in CDLX. Mirabella Financial Services LLP purchased a new position in shares of Cardlytics during the fourth quarter valued at approximately $4,285,000. D. E. Shaw & Co. Inc. lifted its holdings in shares of Cardlytics by 97.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock valued at $4,198,000 after purchasing an additional 558,235 shares during the last quarter. RBF Capital LLC lifted its holdings in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in shares of Cardlytics during the fourth quarter valued at approximately $1,187,000. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CDLX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.